The JAK-STAT pathway is involved in the signaling of multiple cytokines driving cutaneous
inflammation in atopic dermatitis (AD). Janus kinase (JAK) inhibitors target individual …

Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-
severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical …

Existing therapeutics for autoimmune diseases remain problematic due to low efficacy,
severe side effects, and difficulties to reach target tissues. Herein, we design multifunctional …

The recent interest and elucidation of the JAK/STAT signaling pathway created new targets
for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical …

Recent studies on molecular pathways have elucidated novel therapeutic approaches in
inflammatory and autoimmune skin disorders. Specifically, the dysregulation of the Janus …

Rapid progress in genome sequencing technology has put us firmly into a postgenomic era.
A key challenge in biomedical research is harnessing genome sequence to fulfill the …

Background Clinical features and basophil activation levels correlate with serum
autoreactivity and allergen sensitivity in patients with chronic spontaneous urticaria (CSU) …

Introduction Janus kinase (JAK) inhibitors are emerging treatments in dermatology. Also
known as JAKinibs, these agents target JAK-signal transducers and activators of …

Background. Psoriasis is an immune‐mediated, chronic inflammatory disease, and genetic,
immune, oxidative stress (OS), and environmental factors are all thought to contribute to its …

This study was designed to investigate the effects of five Rutaceae family ethanol extracts
(FRFEE): Citrus medica Linn (CML), Citrus aurantium L. Cv. Daidai (CAD), Citrus medica …